SUNDAY November 6, 2011 5:15 pm 852. Characterization of the Expanded Populations of TH17 and T Follicular Helper Cells in New Zealand Black (NZB) Chromosome 1 Congenic Mice Nafiseh Talaei 1 , Carolina Landolt-Marticorena 2 , Babak Noamani 1 , Evelyn Pau 1 , Nan-Hua Chang 3 and Joan E. Wither 1 , 1 Toronto Western Research Institute, Toronto, ON, 2 Toronto Western Hospital and University of Toronto, Toronto, ON, 3 Toronto Western Research Institute, University Health Network, Toronto, ON 5:30 pm 853. Contribution of a Kidney-Infiltrating CD4+ T Cell Clone to Nephritis in Lupus-Prone Mice Akiko Okamoto 1 , Keishi Fujio1 and Kazuhiko Yamamoto 2 , 1 Graduate school of Medicine, The University of Tokyo, Tokyo, Japan, 2 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 5:45 pm 854. Deficient Ubiquitin Ligase Casitas B-Lineage Lymphoma b Expression and Abnormal Peripheral Tolerance in CD4+ T Cells From Systemic Lupus Erythematosus Patients Diana Gomez-Martin, Maria J., Ibarra-Sanchez, Jose Cruz-Ruiz, Jorge Romo-Tena, Jose Esparza-Lopez, Mariana Diaz-Zamudio and Jorge Alcocer-Varela, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico W196b Vasculitis II Moderators: Paul A. Monach, MD, PhD; Boston University; Boston, MA Alfred Mahr, MD, PhD; Hospital Saint-Louis; Paris, France 4:30 pm 855. Prednisone Versus Tamoxifen for Idiopathic Retroperitoneal Fibrosis Augusto Vaglio 1 , Alessandra Palmisano 1 , Stefania Ferretti 1 , Rocco Cobelli 1 , Luigi Boiardi 2 , Carlo Buzio1 and Carlo Salvarani 2 , 1 University of Parma, Parma, Italy, 2 Arcispedale S Maria Nuova, Reggio Emilia, Italy 4:45 pm 856. The Relationship Between Systemic Vasculitis and Retinal Vasculitis James T. Rosenbaum 1 , Jennifer Ku 2 , Amro Ali 2 , Dongseok Choi 2 and Eric B. Suhler 2 , 1 Oregon Health & Science University, Portland, OR, 2 Oregon Health & Science Univ, Portland, OR 5:00 pm 857. Efficacy and Tolerance of Treatments in Patients with Non- Infectious Mixed Cryoglobulinemia Vasculitis: Results From the French Nationwide CryoVas Survey Benjamin Terrier 1 , Evguenia Krastinova 2 , Isabelle Marie 3 , Adeline Lacraz 4 , David Launay 5 , Emmanuelle Plaisier6, Luc de Saint- Martin 7 , Fabrice Bonnet 8 , Pauline Belenotti 9 , Jean-Emmanuel Kahn 10 , Olivier Hinschberger 11 , Patricia Rullier 12 and Patrice Cacoub 13 , 1 Pitié-Salpêtrière Hospital, Paris, France, 2 INSERM U707, Paris, France, 3 Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 4 Nephrology, CHU Bordeaux, Bordeaux, France, 5 Internal Medicine, CHRU Claude Huriez, Lille, France, 6 Nephrology, Tenon Hospital, Paris, France, 7 Internal Medicine, CHU Brest, Brest, France, 8 Internal Medicine, CHU Bordeaux, Bordeaux, France, 9 Internal Medicine, CHU Marseille, Marseille, France, 10 Internal Medicine, Foch Hospital, Suresnes, France, 11 Internal Medicine, CH Mulhouse, Mulhouse, France, 12 Internal Medicine, CHU Montpellier, Montpellier, France, 13 CHU Pitié-Salpêtrière, Paris, France 5:15 pm 858. Churg–Strauss Syndrome: Description and Long-Term Follow-up of the 383 Patients Enrolled In the FVSG Cohort Christian Pagnoux 1 , Chloe Comarmond 2 , Mehdi Khellaf 3 , Jean-Francois Cordier 4 , Mohamed Hamidou 5 , Jean-Francois Viallard 6 , Francois Maurier 7 , Philippe Delaval 8 , Boris Bienvenu 9 , Xavier Puechal 10 , Olivier Aumaître 11 , Marc Ruivard 12 , Alain Le Quellec 13 , Ramiro Cevallos 14 , Olivier Fain 15 , Bertrand Godeau 3 , Raphaèle Seror 2 , Alfred Mahr 16 , Pascal Cohen 17 , Luc Mouthon 18 , Loic Guillevin 19 and French Vasculitis Study Group (FVSG)*, 1 University of Toronto, Toronto, ON, 2 Referral Center for Necrotizing Vasculitides, Hôpital Cochin, AP–HP, Université Paris–Descartes, Paris, France, 3 Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 4 Division of Pneumology, Hôpital Louis- Pradel, Hospices Civils de Lyon, Lyon 1 , Lyon, France, 5 Service de médecine interne, Hôpital Universitaire de Nantes, Nantes, France, Nantes, France, 6 Division of internal Medicine, Hôpital Haut-Lévêque, Université Victor Segalen – Bordeaux 2 , Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Bordeaux, France, 7 Division of internal Medicine, CHR Metz, Metz, Metz, France, 8 Division of Pneumology, Centre Hospitalier Régional Universitaire de Rennes, Rennes, Rennes, France, 9 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, Caen, France, 10 Le Mans General Hospital, Le Mans, France, 11 Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont– Ferrand, Clermont–Ferrand, France, 12 Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont– Ferrand, Clermont–Ferrand, France, 13 Division of internal Medicine, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, Montpellier, France, 14 CH Compiegne, Compiegne, France, 15 Service de médecine interne, Université Paris 13 , AP-HP, Hôpital Jean Verdier, 93140, Bondy, France., Bondy, France, 16 Hospital Saint-Louis, Paris, France, 17 Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, 18 Hopital Cochim, Paris, France, 19 Cochin University Hospital, Paris, France 5:30 pm 859. Surgery Versus Endovascular Repair in Takayasu Arteritis: A Multicenter Study of 166 Procedures David Saadoun 1 , Marc Lambert 2 , Tristan Mirault 3 , Yoland Shoindre 1 , Zahir Amoura 4 , Mathieu Resche Rigon 1 , Pierre yves Hatron 5 , Joseph Emmerich 3 and Patrice P. Cacoub6, 1 Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2 Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Lille, France, 3 Service de Médecine Vasculaire HEGP, Paris, France, 4 CHU Pitié-Salpêtrière, Paris, France, 5 Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 6 Hopital La Pitie, Paris, France 50 2011 <strong>Program</strong> <strong>Book</strong>
5:45 pm 860. Causes and Prognostic Factors of Mortality in Patients with Non-Infectious Mixed Cryoglobulinemia Vasculitis: Results From the French Nationwide CryoVas Survey Benjamin Terrier 1 , Evguenia Krastinova 2 , Isabelle Marie 3 , Adeline Lacraz 4 , David Launay 5 , Emmanuelle Plaisier 6 , Luc de Saint- Martin 7 , Fabrice Bonnet 8 , Pauline Belenotti 9 , Jean-Emmanuel Kahn 10 , Olivier Hinschberger 11 , Patricia Rullier 12 and Patrice Cacoub 13 , 1 Pitié-Salpêtrière Hospital, Paris, France, 2 INSERM U707, Paris, France, 3 Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 4 Nephrology, CHU Bordeaux, Bordeaux, France, 5 Internal Medicine, CHRU Claude Huriez, Lille, France, 6 Nephrology, Tenon Hospital, Paris, France, 7 Internal Medicine, CHU Brest, Brest, France, 8 Internal Medicine, CHU Bordeaux, Bordeaux, France, 9 Internal Medicine, CHU Marseille, Marseille, France, 10 Internal Medicine, Foch Hospital, Suresnes, France, 11 Internal Medicine, CH Mulhouse, Mulhouse, France, 12 Internal Medicine, CHU Montpellier, Montpellier, France, 13 CHU Pitié-Salpêtrière, Paris, France ACR MEET THE PROFESSOR SESSIONS 4:30 - 6:00 pm Admission to the Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for – check the registration code on your ticket matches the code listed below in parentheses. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives on MY ACR at www. rheumatology.org/annual. *Sessions denoted with an asterisk were sold out as of September 12. W187a Crystal: Diagnosis and Management of Gout (021) Speaker: Naomi Schlesinger, MD; University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School; New Brunswick, NJ W185a *Dermatological Manifestations of Rheumatic Diseases (022) Speaker: Nicole Fett, MD; University of Pennsylvania; Philadelphia, PA W186b Immunodeficiency Syndromes (023) Speaker: Alton Melton, MD; Cleveland Clinic; Cleveland, OH W187c Pediatrics: Dermatomyositis (024) P Speaker: Adam Huber, MD; IWK Health Centre; Halifax, NS, Canada W186a Psoriatic Arthritis (025) Speaker: Arthur Kavanaugh, MD; University of California San Diego; San Diego, CA W184d *Rheumatoid Arthritis: Outcome Measures in Clinical Practice PS (026) Speaker: Martin J. Bergman, MD; Taylor Hospital; Ridley Park, PA W185d Systemic Arthritis and Still’s Disease (027) Speaker: Rayfel Schneider, MBBCh, MD; Hospital for Sick Children, University of Toronto; Toronto, ON, Canada W186c *Systemic Lupus Erythematosus: Central Nervous System (028) Speaker: Jorge Sanchez-Guerrero, MD, MS; University Health Network/Mount Sinai Hospital; Toronto, ON, Canada W185bc Temporal Arteritis (029) Speaker: Gene G. Hunder, MD; Mayo Clinic; Rochester, MN W187b *Vasculitis Mimics (030) Speaker: John H. Stone, MD, MPH; Massachusetts General Hospital; Boston, MA ACR SPECIAL SESSION 4:30 - 6:00 pm W474b Legislative Update from Capitol Hill cP Moderator: Timothy Laing, MD; University of Michigan Medical Center; Ann Arbor, MI Upon completion of this session, participants should be able to: • discuss current legislative initiatives in Congress affecting rheumatology • outline the Administration’s role in developing health policy • recognize the value of grassroots advocacy in communicating with Congress ACR REF SPECIAL SESSION 4:30 - 6:00 pm W183c ACR REF Special Session: Clinician Scholar Educator Presentations Ed. Moderators: Abby Goulder Abelson, MD; Cleveland Clinic Foundation; Cleveland, OH Michael J. Battistone, MD; University of Utah Medical Center; Salt Lake City, UT 4:30 pm Introducing the Testimonial-Commentator Format to the Musculoskeletal Curriculum of Medical Students James D. Katz, MD; George Washington Medical Center; Washington, DC SUNDAY November 6, 2011 2011 <strong>Program</strong> <strong>Book</strong> 51
- Page 1 and 2: program B O O K Pre-Conference Cour
- Page 3 and 4: program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6: TABLE OF CONTENTS POLICIES Copyrigh
- Page 7 and 8: TABLE OF CONTENTS ACR Immunology Up
- Page 9 and 10: TABLE OF CONTENTS Vasculitis Poster
- Page 11 and 12: However, the ACR continues to requi
- Page 13 and 14: MEETING NAVIGATION GUIDE To navigat
- Page 15 and 16: Newsroom Located in room W175c, use
- Page 17: Guided Poster Tours Guided poster t
- Page 20 and 21: FRIDAY November 4, 2011 9:15 am Ult
- Page 22 and 23: SATURDAY, NOVEMBER 5, 2011 12:00 -
- Page 24 and 25: SATURDAY November 5, 2011 8:35 am T
- Page 26 and 27: SATURDAY November 5, 2011 Pain: Pat
- Page 28 and 29: SUNDAY November 6, 2011 SUNDAY, NOV
- Page 30 and 31: SUNDAY November 6, 2011 Upon comple
- Page 32 and 33: EXHIBITS 10:00 am - 5:00 pm INNOVAT
- Page 34 and 35: SUNDAY November 6, 2011 ARHP SPECIA
- Page 36 and 37: SUNDAY November 6, 2011 W179b Rheum
- Page 38 and 39: 3:15 pm 732. Notch Signaling Pathwa
- Page 40 and 41: SUNDAY November 6, 2011 3:15 pm 756
- Page 42 and 43: SUNDAY November 6, 2011 Children’
- Page 44 and 45: SUNDAY November 6, 2011 3:00 pm 791
- Page 46 and 47: 3:30 pm Demonstration and Practice
- Page 48 and 49: Yasser M. El Miedany 1 , Maha El Ga
- Page 50 and 51: SUNDAY November 6, 2011 48 Musculos
- Page 54 and 55: SUNDAY November 6, 2011 52 4:55 pm
- Page 56 and 57: MONDAY, NOVEMBER 7, 2011 ACR/ARHP R
- Page 58 and 59: MONDAY November 7, 2011 W185a Scler
- Page 60 and 61: MONDAY November 7, 2011 Upon comple
- Page 62 and 63: Upon completion of this session, pa
- Page 64 and 65: MONDAY November 7, 2011 W187b Basic
- Page 66 and 67: MONDAY November 7, 2011 2:30 pm Cel
- Page 68 and 69: MONDAY November 7, 2011 Indianapoli
- Page 70 and 71: 3:45 pm 1628. Association of Knee P
- Page 72 and 73: MONDAY November 7, 2011 Glostrup, C
- Page 74 and 75: MONDAY November 7, 2011 3:33 pm A R
- Page 76 and 77: MONDAY November 7, 2011 4:30 pm Ris
- Page 78 and 79: Institutet, Stockholm, Sweden, 6 Un
- Page 80 and 81: 5:45 pm 1700. Successful Dose De-Es
- Page 82 and 83: MONDAY November 7, 2011 Michigan, A
- Page 84 and 85: MONDAY November 7, 2011 4:45 pm 172
- Page 86 and 87: MONDAY November 7, 2011 5:25 pm Imp
- Page 88 and 89: TUESDAY November 8, 2011 ARHP CONCU
- Page 90 and 91: TUESDAY November 8, 2011 9:25 am Is
- Page 92 and 93: ACR PRACTICE ISSUE 9:30 - 10:30 am
- Page 94 and 95: TUESDAY November 8, 2011 noon 2431.
- Page 96 and 97: TUESDAY November 8, 2011 W186b Vasc
- Page 98 and 99: ACR CLINICAL SYMPOSIA 2:30 - 4:00 p
- Page 100 and 101: TUESDAY November 8, 2011 3:45 pm 24
- Page 102 and 103:
TUESDAY November 8, 2011 University
- Page 104 and 105:
TUESDAY November 8, 2011 and Oncolo
- Page 106 and 107:
Italy, 3 Hospital Universitario La
- Page 108 and 109:
3:10 pm Case Study Diane V. Lacaill
- Page 110 and 111:
• discuss the evidence to support
- Page 112 and 113:
TUESDAY November 8, 2011 4:45 pm 25
- Page 114 and 115:
5:15 pm 2532. Selection of Patients
- Page 116 and 117:
TUESDAY November 8, 2011 ACR/ARHP C
- Page 118 and 119:
WEDNESDAY, NOVEMBER 9, 2011 ACR/ARH
- Page 120 and 121:
9:00 am Mechanisms of Thrombosis in
- Page 122 and 123:
WEDNESDAY November 9, 2011 A. Kopec
- Page 124 and 125:
WEDNESDAY November 9, 2011 9:15 am
- Page 126 and 127:
WEDNESDAY November 9, 2011 9:45 am
- Page 128 and 129:
WEDNESDAY November 9, 2011 11:45 am
- Page 130 and 131:
WEDNESDAY November 9, 2011 Graduate
- Page 132 and 133:
11:00 am The Process: Defining Appr
- Page 134 and 135:
ACR Poster Session A 11. Myocardial
- Page 136 and 137:
ACR Poster Session A 37. Regulation
- Page 138 and 139:
ACR Poster Session A 64. Interleuki
- Page 140 and 141:
ACR Poster Session A Mexico City, M
- Page 142 and 143:
ACR Poster Session A 121. An Analys
- Page 144 and 145:
ACR Poster Session A 146. National
- Page 146 and 147:
ACR Poster Session A 165. Genome-Wi
- Page 148 and 149:
ACR Poster Session A 185. US Examin
- Page 150 and 151:
ACR Poster Session A Jones 1 , Andr
- Page 152 and 153:
ACR Poster Session A Gerald J. D. H
- Page 154 and 155:
ACR Poster Session A 258. Etanercep
- Page 156 and 157:
ACR Poster Session A GA, 6 Hospital
- Page 158 and 159:
ACR Poster Session A 305. Pathway-B
- Page 160 and 161:
ACR Poster Session A 328. Near Miss
- Page 162 and 163:
ACR Poster Session A 351. A Novel M
- Page 164 and 165:
ACR Poster Session A Sugihara 6 , K
- Page 166 and 167:
ACR Poster Session A 398. Rituximab
- Page 168 and 169:
ACR Poster Session A & Johnson Phar
- Page 170 and 171:
ACR Poster Session A 436. Predicted
- Page 172 and 173:
ACR Poster Session A Tomomi Tsuru 1
- Page 174 and 175:
ACR Poster Session A 479. Follow up
- Page 176 and 177:
ACR Poster Session A 496. A Chimeri
- Page 178 and 179:
ACR Poster Session A 518. Associati
- Page 180 and 181:
ACR Poster Session A Piestany, Slov
- Page 182 and 183:
ACR Poster Session A 576. Fn14 Defi
- Page 184 and 185:
ACR Poster Session A 593. Plasma Le
- Page 186 and 187:
ACR Poster Session A 611. Why Do Lu
- Page 188 and 189:
ACR Poster Session A 634. Associati
- Page 190 and 191:
ACR Poster Session A Alarcon-Riquel
- Page 192 and 193:
ACR Poster Session A Laboratories,
- Page 194 and 195:
ACR Poster Session A Movsisyan, Lid
- Page 196 and 197:
ACR Poster Session A Th1 Cells Expa
- Page 198 and 199:
ACR/ARHP Poster Session B College o
- Page 200 and 201:
ACR/ARHP Poster Session B 920. Econ
- Page 202 and 203:
ACR/ARHP Poster Session B Study. A.
- Page 204 and 205:
ACR/ARHP Poster Session B 974. Dise
- Page 206 and 207:
ACR/ARHP Poster Session B 1001. Mic
- Page 208 and 209:
ACR/ARHP Poster Session B 206 Khann
- Page 210 and 211:
ACR/ARHP Poster Session B 208 Pulmo
- Page 212 and 213:
ACR/ARHP Poster Session B Swearinge
- Page 214 and 215:
ACR/ARHP Poster Session B 212 Felds
- Page 216 and 217:
ACR/ARHP Poster Session B 214 Corbi
- Page 218 and 219:
ACR/ARHP Poster Session B 1161. End
- Page 220 and 221:
ACR/ARHP Poster Session B 1182. Uri
- Page 222 and 223:
ACR/ARHP Poster Session B 1205. A S
- Page 224 and 225:
ACR/ARHP Poster Session B 222 Murth
- Page 226 and 227:
ACR/ARHP Poster Session B San Diego
- Page 228 and 229:
ACR/ARHP Poster Session B 1266. Eva
- Page 230 and 231:
ACR/ARHP Poster Session B 1296. Pat
- Page 232 and 233:
ACR/ARHP Poster Session B 230 1320.
- Page 234 and 235:
ACR/ARHP Poster Session B 1348. Syn
- Page 236 and 237:
ACR/ARHP Poster Session B 1375. Ant
- Page 238 and 239:
ACR/ARHP Poster Session B 1398. Cli
- Page 240 and 241:
ACR/ARHP Poster Session B Baltimore
- Page 242 and 243:
ACR/ARHP Poster Session B 1451. Ele
- Page 244 and 245:
ACR/ARHP Poster Session B Sclerosis
- Page 246 and 247:
ACR/ARHP Poster Session B 1496. Evi
- Page 248 and 249:
ACR/ARHP Poster Session B 1518. Pro
- Page 250 and 251:
ACR/ARHP Poster Session B Hagen 1 ,
- Page 252 and 253:
ACR/ARHP Poster Session B ARHP Clin
- Page 254 and 255:
ACR/ARHP Poster Session C Karl Eger
- Page 256 and 257:
ACR/ARHP Poster Session C Tampere S
- Page 258 and 259:
ACR/ARHP Poster Session C 256 1 Jun
- Page 260 and 261:
ACR/ARHP Poster Session C Universit
- Page 262 and 263:
ACR/ARHP Poster Session C 1864. Epi
- Page 264 and 265:
ACR/ARHP Poster Session C 262 Hospi
- Page 266 and 267:
ACR/ARHP Poster Session C 2 Biogen
- Page 268 and 269:
ACR/ARHP Poster Session C 1945. Cir
- Page 270 and 271:
ACR/ARHP Poster Session C 268 1974.
- Page 272 and 273:
ACR/ARHP Poster Session C 2003. Eff
- Page 274 and 275:
ACR/ARHP Poster Session C Hosp Gast
- Page 276 and 277:
ACR/ARHP Poster Session C Toronto,
- Page 278 and 279:
ACR/ARHP Poster Session C Francisco
- Page 280 and 281:
ACR/ARHP Poster Session C 2105. Inc
- Page 282 and 283:
ACR/ARHP Poster Session C Universit
- Page 284 and 285:
ACR/ARHP Poster Session C 282 2151.
- Page 286 and 287:
ACR/ARHP Poster Session C 284 2175.
- Page 288 and 289:
ACR/ARHP Poster Session C 286 2196.
- Page 290 and 291:
ACR/ARHP Poster Session C 2217. Lon
- Page 292 and 293:
ACR/ARHP Poster Session C Research
- Page 294 and 295:
ACR/ARHP Poster Session C 2258. sIL
- Page 296 and 297:
ACR/ARHP Poster Session C 2290. The
- Page 298 and 299:
ACR/ARHP Poster Session C Universit
- Page 300 and 301:
ACR/ARHP Poster Session C 2345. IL-
- Page 302 and 303:
ACR/ARHP Poster Session C 2376. Gra
- Page 304 and 305:
ACR/ARHP Poster Session C 2399. Spe
- Page 306 and 307:
REF Industry Roundtable-supported S
- Page 308 and 309:
REF Industry Roundtable-supported S
- Page 310 and 311:
Industry-supported POST-CONFERENCE
- Page 312 and 313:
CERTIFICATES OF CME CREDIT OR PARTI
- Page 314 and 315:
2011 ACR/ARHP Annual Meeting Leader
- Page 316 and 317:
2011 ACR/ARHP Annual Meeting Leader
- Page 318 and 319:
EXHIBITORS Abbott Pharmaceuticals B
- Page 320 and 321:
EXHIBITORS Lippincott, Williams and
- Page 322 and 323:
acknowledgements The ACR, the ARHP
- Page 324 and 325:
Invited Speaker /Moderator Index 32
- Page 326 and 327:
Invited Speaker /Moderator Index 32
- Page 328 and 329:
Invited Speaker /Moderator Index Ev
- Page 330 and 331:
Invited Speaker /Moderator Index 32
- Page 332 and 333:
Invited Speaker /Moderator Index 33
- Page 334 and 335:
Invited Speaker /Moderator Index Mu
- Page 336 and 337:
Invited Speaker /Moderator Index Om
- Page 338 and 339:
Invited Speaker /Moderator Index St
- Page 340 and 341:
Invited Speaker /Moderator Index Wi
- Page 342 and 343:
aBSTRACT author Index 340 Alpers, C
- Page 344 and 345:
aBSTRACT author Index Bawa, WA 259
- Page 346 and 347:
aBSTRACT author Index 344 Broder, A
- Page 348 and 349:
aBSTRACT author Index 346 Chaves, L
- Page 350 and 351:
aBSTRACT author Index 348 Dalbeth,
- Page 352 and 353:
aBSTRACT author Index Eastman, PS 3
- Page 354 and 355:
aBSTRACT author Index 352 Fragoso-L
- Page 356 and 357:
aBSTRACT author Index Gordon, C 4,
- Page 358 and 359:
aBSTRACT author Index Hemmati, I 13
- Page 360 and 361:
aBSTRACT author Index 358 Ishigatsu
- Page 362 and 363:
aBSTRACT author Index 360 Keeling,
- Page 364 and 365:
aBSTRACT author Index 362 Kumar, V
- Page 366 and 367:
aBSTRACT author Index 364 Lim, M 13
- Page 368 and 369:
aBSTRACT author Index 366 Marshall,
- Page 370 and 371:
aBSTRACT author Index 368 MMF/AZA L
- Page 372 and 373:
aBSTRACT author Index 370 Noel, D 1
- Page 374 and 375:
aBSTRACT author Index 372 Pawlita,
- Page 376 and 377:
aBSTRACT author Index 374 Ramos, I
- Page 378 and 379:
aBSTRACT author Index 376 Rönnblom
- Page 380 and 381:
aBSTRACT author Index 378 Shaykevic
- Page 382 and 383:
aBSTRACT author Index Su, J 22, 139
- Page 384 and 385:
aBSTRACT author Index 382 Tomcik, M
- Page 386 and 387:
aBSTRACT author Index 384 Villeneuv
- Page 388 and 389:
aBSTRACT author Index 386 Wu, X 650
- Page 390 and 391:
abstract keyword Index 388 18FDG PE
- Page 392 and 393:
abstract keyword Index 2092, 2113,
- Page 394 and 395:
abstract keyword Index 392 macropha
- Page 396 and 397:
abstract keyword Index 387, 388, 38
- Page 398 and 399:
Abstract Moderator disclosure A Ano
- Page 400 and 401:
Abstract Moderator disclosure Jonas
- Page 402 and 403:
V van der Heijde, Desiree, MD, PhD
- Page 404 and 405:
Notes 402 2011 Program Book
- Page 406 and 407:
immunosuppressive agents is not rec
- Page 408:
In appropriate patients with psoria